Shabir Hasham

pharmafile | May 6, 2022 | Appointment | |   

Shabir Hasham has served as Santhera’s Global Development Program Lead & Global Head Medical Affairs for the past three years, where he was responsible for overseeing the clinical development and regulatory submission of vamolorone, for the treatment of Duchenne muscular dystrophy (DMD). 

“I am thrilled to be taking on the role of CMO at such a transformative point in the Company’s trajectory,” said Shabir Hasham, MD. “I look forward to helping drive Santhera’s mission in advancing vamorolone towards approval, first in the US, and later in Europe, and clinically progressing lonodelestat, whilst working with the medical communities to leverage the transformational potential of our pipeline products in and beyond DMD and cystic fibrosis, respectively.”

Related Content

No items found

Latest content